{
  "abstract": "Background Evidence on the comparative effectiveness of different surveillance patterns in patients with hepatitis B virus (HBV)-related cirrhosis receiving antiviral therapy is limited. We aimed to characterize HCC surveillance patterns and evaluate their associations with early-stage HCC detection in this population.Methods This retrospective-prospective cohort study included 434 patients with HBV-related cirrhosis on nucleos(t)ide analogue therapy who developed HCC at Beijing You’an Hospital between January 2009 and December 2025. Surveillance imaging in the 12 months before HCC diagnosis was categorized as CT/MRI, ultrasound plus triple-biomarker (AFP, AFP-L3 and DCP), ultrasound alone, or no imaging. The outcome was early-stage HCC detection, defined as Barcelona Clinic Liver Cancer (BCLC) stage 0 or A. Multivariable logistic regression was used to evaluate associations between surveillance patterns and early-stage HCC detection.Results 353 (81.3%) patients received surveillance imaging in the year prior to HCC diagnosis, whereas 81 (18.7%) had no imaging. Among the 353 patients who received surveillance, 50 (14.2%) had ultrasound alone, 187 (53.0%) had ultrasound plus triple-biomarker, and 116 (32.9%) had CT/MRI. Over the study period, CT/MRI use increased from 17.4% to 30.5%, while ultrasound alone declined. Early-stage HCC detection rates increased progressively from no imaging (55.6%), ultrasound alone (60.0%), ultrasound plus triple-biomarker (71.7%), to CT/MRI (82.8%) (P<0.001, IDDF2026-ABS-0083 Figure 1). In multivariable logistic regression, CT/MRI (OR, 0.247; 95% CI, 0.117–0.505, P<0.001) and ultrasound plus triple-biomarker (OR, 0.555; 95% CI, 0.307–1.000, P=0.049) were independently associated with reduced odds of non-early-stage HCC detection compared with no imaging, whereas ultrasound alone was not (P=0.977). CT/MRI-based surveillance was associated with significantly higher early-stage detection compared to both ultrasound alone (82.8% vs 60.0%, P=0.003) and ultrasound plus triple-biomarker (82.8% vs 71.7%, P=0.040) (IDDF2026-ABS-0083 Figure 2). Among ultrasound-based groups, higher surveillance frequency improved early-stage detection only in the ultrasound-alone group, whereas detection rates remained consistently high regardless of frequency in the ultrasound plus triple-biomarker and CT/MRI groups (IDDF2026-ABS-0083 Figure 3).Conclusions In patients with HBV-related cirrhosis receiving antiviral therapy, CT/MRI and ultrasound plus triple-biomarker, but not ultrasound alone, independently improved early-stage HCC detection. Optimizing surveillance quality through appropriate modality selection may be more effective than increasing surveillance frequency.Abstract IDDF2026-ABS-0083 Figure 1Abstract IDDF2026-ABS-0083 Figure 2Abstract IDDF2026-ABS-0083 Figure 3",
  "authors": [
    {
      "affiliations": [
        "Beijing You’an Hospital Affiliated to Capital Medical University, China"
      ],
      "name": "Yaxin Li"
    },
    {
      "affiliations": [
        "Beijing You’an Hospital Affiliated to Capital Medical University, China"
      ],
      "name": "Yuwei Wang"
    },
    {
      "affiliations": [
        "Beijing You’an Hospital Affiliated to Capital Medical University, China"
      ],
      "name": "Ying Han"
    },
    {
      "affiliations": [
        "Beijing You’an Hospital Affiliated to Capital Medical University, China"
      ],
      "name": "Huiguo Ding"
    }
  ],
  "title": "IDDF2026-ABS-0083 Hepatocellular carcinoma surveillance patterns and early detection in patients with hepatitis B-related cirrhosis",
  "uid": "157a35c0-201d-5176-ac00-d85d2c9b59cd"
}